Medical Use
Pepaxto is an alkylating agent used in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma (RRMM). This treatment is for those who have undergone at least four prior therapies and whose cancer is resistant to at least one immunomodulatory agent, one proteasome inhibitor, and one CD38-directed monoclonal antibody.
Recommended Dosage: Administer Pepaxto at a dose of 40 mg intravenously over 30 minutes on Day 1 of each 28-day cycle, continuing until disease progression or unacceptable toxicity occurs. Dexamethasone should be given at 40 mg orally or intravenously on Days 1, 8, 15, and 22 of each cycle. For patients aged 75 years or older, reduce the dexamethasone dose to 20 mg.
Warning & Precautions
Thrombocytopenia: Patients receiving melphalan flufenamide with dexamethasone may experience thrombocytopenia. Monitor platelet counts regularly, especially during the first 2 months of treatment. Do not administer if platelet count is below 50 x 10^9/L.
Neutropenia: Neutropenia has been observed in patients treated with Pepaxto and dexamethasone. Regularly monitor neutrophil counts, particularly during the first 2 months. Do not administer if the absolute neutrophil count is below 1 x 10^9/L.
Anemia: Anemia has occurred in patients receiving melflufen (Pepaxto) with dexamethasone. Monitor red blood cell counts frequently, especially in the initial 2 months. Dosage adjustments or delays may be necessary to allow RBC recovery.
Secondary Malignancies: Patients with multiple myeloma treated with this alkylating drug may develop secondary malignancies such as acute leukemia or myelodysplastic syndromes. Long-term monitoring for secondary cancers is essential.
Fetal Harm: Pepaxto 20 mg injection can cause fetal harm due to its genotoxic nature and targeting of actively dividing cells. Women of reproductive potential should use effective contraception during treatment and for 6 months after the final dose.
Breastfeeding: Due to the potential for severe side effects in breastfed children, women should not breastfeed during treatment with Pepaxto and for 7 days after the final dose.
Documentation Availability
Documents required to import PEPAXTO to India?
PEPAXTO (melphalan flufenamide) injection can be imported by patients or treating physicians on behalf of patients. The following documentation is required to import the product:
- (i)2 ID proofs along with PAN card details along with attested scanned copies
- (ii)Valid doctor prescription scanned copy
- (iii)Doctor’s MCI number
- (iv)Doctor’s mobile number
- (v)Patients diagnostic reports
How is the order confirmed?
The order will be confirmed only after the receipt of:
- (i)The above-mentioned documents and drug availability.
- (ii)Import permit if applicable.
Sourcing & Delivery
The Rx4U team has extensive experience in sourcing PEPAXTO (Cancer Treatment Medicines) from around the world, ensuring global access to the best available treatments for our customers. We are dedicated to promptly dispensing any valid prescription. All prescriptions are verified and dispatched directly to the patient’s address. Our patients are our top priority, and we strive to improve their lives through our services.
FAQ
What is the generic name for the trade name drug Pepaxto®?
The generic name for Pepaxto® is melphalan flufenamide.
Who manufactures Pepaxto 20 mg?
Pepaxto 20 mg is manufactured by Oncopeptides AB.
Is Pepaxto® FDA approved?
Yes, Pepaxto® was approved by the FDA on February 26, 2021.
What is Pepaxto®?
Pepaxto® is an anticancer peptide-drug conjugate used in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.
What dosage and form is Pepaxto® available in?
Pepaxto® is available as an injection: 20 mg of melphalan flufenamide in a lyophilized powder form, supplied in a single-dose vial for reconstitution and dilution for intravenous use.
How is Pepaxto® administered?
Pepaxto® is administered at a dose of 40 mg intravenously over 30 minutes on Day 1 of each 28-day treatment cycle, in combination with dexamethasone.
What are the most common side effects of Pepaxto®?
Common side effects of Pepaxto® include nausea, fatigue, diarrhea, fever, and respiratory tract infection.
How much does Pepaxto® cost in India?
The cost of Pepaxto® in India is quite reasonable. To purchase this medication legally, you can reach out to Rx4u team.
What are the storage conditions for Pepaxto®?
Store Pepaxto® refrigerated at 2 to 8°C (36 to 46°F) and protect it from light. Keep it in the original carton until use.
Is it safe to buy Pepaxto® online in India?
Yes, you can safely purchase Pepaxto® online in India through https://rx4u.in/.
*Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and Rx4U does not lay any claim on them we only provide Information.
